Iron chelation and multiple sclerosis

ASN Neuro

Volumn 6, Issue 1, 2014, Pages 43-63

  Weigel, Kelsey J ^a   Lynch, Sharon G ^b   Levine, Steven M ^b  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Deferasirox; Deferiprone; Deferoxamine; Experimental autoimmune encephalomyelitis; Iron deposition

Indexed keywords

AMYLOID BETA PROTEIN; APOFERRITIN; CASPASE 3; CLIOQUINOL; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PRESENILIN 1; PROTEOLIPID PROTEIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; AXONAL INJURY; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DEFENSE MECHANISM; DEMYELINATING DISEASE; DIARRHEA; EXPANDED DISABILITY STATUS SCALE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FATIGUE; FUNCTIONAL STATUS SCALE; HEARING IMPAIRMENT; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INTERNATIONAL COOPERATIVE ATAXIA RATING SCALE; IRON CHELATION; IRON TRANSPORT; MICROGLIA; MULTIPLE SCLEROSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

EID: 84893827205     PISSN: 17590914     EISSN: None     Source Type: Journal    
DOI: 10.1042/AN20130037     Document Type: Article

References (229)

1. Abbruzzese G, Cossu G, Balocco M, Marchese R, Murgia D, Melis M, Galanello R, Barella S, Matta G, Ruffinengo U, Bonuccelli U, Forni GL (2011) A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 96:1708-1711.
2. Adams CW (1988) Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry 51:260-265.
3. Adams CW (1989) A Color Atlas of Multiple Sclerosis and Other Myelin Disorders. Dobbs Ferry, NY: Sheridan House Inc.
4. Al-Radaideh AM, Wharton SJ, Lim SY, Tench CR, Morgan PS, Bowtell RW, Constantinescu CS, Gowland PA (2013) Increased iron accumulation occurs in the earliest stages of demyelinating disease: an ultra-high field susceptibility mapping study in Clinically Isolated Syndrome. Mult Scler 19:896-903.
5. Amor S, Puentes F, Baker D, van der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology 129:154-169.
6. Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, Martins RN (2003) Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res Brain Res Rev. 43:1-16.
7. Baek JH, Reiter CE, Manalo DJ, Buehler PW, Hider RC, Alayash AI (2011) Induction of hypoxia inducible factor (HIF-1α) in rat kidneys by iron chelation with the hydroxypyridinone, CP94.Biochim Biophys Acta 1809:262-268.
8. Bagnato F, Hametner S, Yao B, van Gelderen P, Merkle H, Cantor FK, Lassmann H, Duyn JH (2011) Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 134:3602-3615.
9. Bagnato F, Hametner S, Welch EB (2013) Visualizing iron in multiple sclerosis. Magn Reson Imaging 31:376-384.
10. Bakshi R, Miletich R, Kinkel P, Emmet M, Kinkel W (1998) High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging 8:228-234.
11. Bakshi R, Shaikh Z, Janardhan V (2000) MRI T2 shortening ('black T2') in multiple sclerosis: frequency, location, and clinical correlation. NeuroReport 11:15-21.
12. Bakshi R, Benedict R, Bermel R, Caruthers S, Puli S, Tjoa CW, Fabiano AJ, Jacobs L (2002) T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 59:62-68.
13. Bartfay WJ, Lehotay DC, Sher GD, Bartfay E, Tyler B, Luo X, Liu PP (1999) Erythropoiesis: comparison of cytotoxic aldehyde generation in beta-thalassemia patients chelated with deferoxamine or deferiprone (L1) versus NO chelation. Hematology 4:67-76.
14. Beard JL (2001) Iron biology in immune function, muscle metabolism, and neuronal functioning. J Nutr 131:568S-579S.
15. Beard JL, Wiesinger JA, Connor JR (2003) Pre- and postweaning iron deficiency alters myelination in Sprague-Dawley rats. Dev Neurosci 25:308-315.
16. Benarroch EE (2009) Oligodendrocytes: susceptibility to injury and involvement in neurologic disease. Neurology 72:1779-1785.
17. Ben-Shachar D, Eshel G, Finberg JP, Youdim MB (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56:1441-1444.
18. Ben-Shachar D, Eshel G, Riederer P, Youdim MB (1992) Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. Ann Neurol 32 (Suppl):S105-S110.
19. Bermel RA, Puli SR, Rudick RA, Weinstock-Guttman B, Fisher E, Munschauer FE 3rd, Bakshi R (2005) Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 62:1371-1376.
20. Bian K, Gao Z, Weisbrodt N, Murad F (2003) The nature of heme/iron-induced protein tyrosine nitration. Proc Natl Acad Sci USA 100:5712-5717.
21. Boddaert N, Le Quan Sang KH, Rötig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI (2007) Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110:401-408.
22. Bolton C, Paul C (2006) Glutamate receptors in neuroinflammatory demyelinating disease. Mediators Inflamm 2006:93684.
23. Bowern N, Ramshaw IA, Clark IA, Doherty PC (1984) Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. J Exp Med 160:1532-1543.
24. Brass S, Benedict R, Weinstock-Guttman B, Munschauer F, Bakshi R (2006) Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler 12:437-444.
25. Brittenham GM (2011) Iron-chelating therapy for transfusional iron overload. N Engl J Med 364:146-156.
26. Britton R, Leicester K, Bacon B (2002) Iron toxicity and chelation therapy. Int J Hematol. 76:219-228.
27. Calabrese V, Scapagnini G, Ravagna A, Bella R, Butterfield D, Calvani M, Pennisi G, Guiffrida Stella AM (2003) Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res 28:1321-1328.
28. Cappellini MD, Pattoneri P (2009) Oral iron chelators. Annu Rev Med 60:25-38.
29. Cappellini MD, Musallam KM, Taher AT (2009) Overview of iron chelation therapy with desferrioxamine and deferiprone. Hemoglobin 33 (Suppl 1):S58-S69.
30. Castellani RJ, Siedlak SL, Perry G, Smith MA (2000) Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol 100:111-114.
31. Castellani RJ, Moreira PI, Perry G, Zhu X (2012) The role of iron as a mediator of oxidative stress in Alzheimer disease. Biofactors 38:133-138.
32. Ceccarelli A, Filippi M, Neema M, Arora A, Valsasina P, Rocca MA, Healy BC, Bakshi R (2009) T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. Mult Scler 15:678-686.
33. Ceccarelli A, Rocca MA, Neema M, Martinelli V, Arora A, Tauhid S, Ghezzi A, Comi G, Bakshi R, Filippi M (2010) Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Mult Scler 16:39-44.
34. Ceccarelli A, Rocca MA, Perego E, Moiola L, Ghezzi A, Martinelli V, Comi G, Filippi M (2011) Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis. Mult Scler 17:702-707.
35. Chakrabarty A, Emerson M, LeVine SM (2003) Heme oxygenase-1 in SJL mice with experimental allergic encephalomyelitis. Mult Scler 9:372-381.
36. Chinnery PF, Crompton DE, Birchall D, Jackson MJ, Coulthard A, Lombès A (2007) Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 130:110-119.
37. Choi BY, Jang BG, Kim JH, Seo JN, Wu G, Sohn M, Chung TN, Suh SW (2013) Copper/zinc chelation by clioquinol reduces spinal cord white matter damage and behavioral deficits in a murine MOG-induced multiple sclerosis model. Neurobiol Dis. 54:382-391.
38. Choi I, Lee S, Denney D, Lynch S (2011) Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T. Mult Scler 17:289-296.
39. Chora AA, Fontoura P, Cunha A, Pais TF, Cardoso S, Ho PP (2007) Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clin Invest 117:438-447.
40. Connor JR, Menzies SL (1995) Cellular management of iron in the brain. J Neurol Sci 134 (Suppl):33-44.
41. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB (1996) The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 271:20291-20299.
42. Craelius W, Migdal M, Luessenhop C, Sugar A, Mihalakis I (1982) Iron deposits surrounding multiple sclerosis plaques. Arch Pathol Lab Med 106:397-399.
43. Cragg L, Hebbel RP, Miller W, Solovey A, Selby S, Enright H (1998) The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood 92:632-638.
44. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF (1991) Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337:1304-1308.
45. Crichton RR, Dexter DT, Ward RJ (2011) Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm 118:301-314.
46. Crowe A, Morgan EH (1994) Effects of chelators on iron uptake and release by the brain in the rat. Neurochem Res 19:71-76.
47. Del Vecchio GC, Schettini F, Piacente L, De Santis A, Giordano P, De Mattia D (2002) Effects of deferiprone on immune status and cytokine pattern in thalassaemia major. Acta Haematol 108:144-149.
48. Deng X, Vidal R, Englander E (2010) Accumulation of oxidative DNA damage in brain mitochondria in mouse model of hereditary ferritinopathy. Neurosci Lett 479:44-48.
49. Desferal prescribing information [Internet]. East Hanover (NJ): Novartis Pharmaceuticals Corporation. (c2011), Available from: http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/desferal.pdf
50. Devos D, Moreau C, Devedijan JC, Kluza J, Laloux C, Jonneaux A, Petrault M, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik IZ, Bordet R (2013) Targeting chelatable iron as a therapeutic modality in Parkinson's disease, Antioxid Redox Signal, in the press.
51. Dexter D, Statton SA, Whitmore C, Freinbichler W, Weinberger P, Tipton KF, Della Corte L, Ward RJ, Crichton RR (2011) Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J Neural Transm 118:223-231.
52. Domercq M, Sánchez-Gómez M, Sherwin C, Etxebarria E, Fern R, Matule C (2007) System xc- and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes. J Immunol 178:6549-6556.
53. EXJADE prescribing information [Internet]. East Hanover (NJ): Novartis Pharmaceuticals Corporation. (c2012), Available from: http://www.us.exjade.com/health-care-professional/safetyprofile.jsp?usertrack.filter_applied=true&NovaId=4029462082237025223.
54. Eybl V, Kotyzová D, Kolek M, Koutenský J, Nielsen P (2002) The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice. Toxicol Lett 128:169-175.
55. Fabriek BO, Dijkstra CD, van den Berg TK (2005) The macrophage scavenger receptor CD163. Immunobiology 210:153-160.
56. Fearnley JM, Stevens JM, Rudge P (1995) Superficial siderosis of the central nervous system. Brain 118:1051-1066.
57. Febbraro F, Andersen K, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M (2013) Chronic intransal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model. Exp Neurol 247:45-58.
58. Fernandes J (2012) Iron chelation therapy in the management of transfusion-related cardiac iron overload. Transfusion 52:2256-2268.
59. Fernanades SP, Dringen R, Lawen A, Robinson SR (2011) Inactivation of astrocytic glutamine synthetase by hydrogen peroxide requires iron. Neurosci Lett 490:27-30.
60. Ferretti G, Bacchetti T, DiLudovico F, Viti B, Angeleri VA, Danni M, Provinciali L (2006) Intracellular oxidative activity and respiratory burst of leukocytes isolated from multiple sclerosis patients. Neurochem Int 48:87-92.
61. FERRIPROX prescribing information [Internet]. Rockville (MD): ApoPharma USA, Inc. (c2011), Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf
62. Fine JM, Baillargeon AM, Renner DB, Hoerster NS, Tokarev J, Colton S, Pelleg A, Andrews A, Sparley KA, Krogh KM, Frey WH, Hanson LR (2012) Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice. Exp Brain Res 219:381-390.
63. Finkenstedt A, Wolf E, Höfner E, Gasser BI, Bösch S, Bakry R, Creus M, Kremser C, Schocke M, Theurl M, Moser P, Schranz M, Bonn G, Poewe W, Vogel W, Janecke AR, Zoller H (2010) Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J Hepatol 53:1101-1107.
64. Fisher A, Naughton D (2005) Therapeutic chelators for the twenty first century: new treatments for iron and copper mediated inflammatory and neurological disorders. Curr Drug Deliv 2:261-268.
65. Forge J, Pedchenko T, LeVine SM (1998) Iron deposits in the central nervous system of SJL mice with experimental allergic encephalomyelitis. Life Sci 63:2271-2284.
66. Forni GL, Balocco M, Cremonesi L, Abbruzzese G, Parodi RC, Marchese R (2008) Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord 23:904-907.
67. Fredenburg A, Sethi R, Allen D, Yokel R (1996) The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. Toxicology 108:191-199.
68. Furukawa T, Naitoh Y, Kohno H, Tokunaga R, Taketani S (1992) Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis. Life Sci 50:2059-2065.
69. Galicia G, Maes W, Verbinnen B, Kasran A, Bullens D, Arredouani M, Ceuppens JL (2009) Haptoglobin deficiency facilitates the development of autoimmune inflammation. Eur J Immunol 39:3404-3412.
70. Gallyas F, Környey S (1968) [A further contribution to the knowledge of the Hallervorden-Spatz disease]. Arch Psychiatr Nervenkr. 212:33-45.
71. Ge Y, Jensen JH, Lu H, Helpern JA, Miles L, Inglese M, Babb JS, Herbert J, Grossman RI (2007) Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 28:1639-1644.
72. Germanò A, Caffo M, Angileri FF, Arcadi F, Newcomb-Fernandez J, Caruso G, Meli F, Pineda JA, Lewis SB, Wang KK, Bramanti P, Costa C, Hayes RL (2007) NMDA receptor antagonist felbamate reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat. J Neurotrauma 24:732-744.
73. Ghoti H, Fibach E, Merkel D, Perez-Avraham G, Grisariu S, Rachmilewitz EA (2010) Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica 95:1433-1434.
74. Glickstein H, El RB, Link G, Breuer W, Konjin A, Hershko C, Nick H, Cabantchik ZI (2006) Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 108:3195-3203.
75. Golding S, Young SP (1995) Iron requirements of human lymphocytes: relative contribution of intra- and extra-cellular iron. Scand J Immunol 41:229-236.
76. Grant SM, Wiesinger JA, Beard JL, Cantorna MT (2003) Iron deficient mice fail to develop autoimmune encephalomyelitis. J Nutr 133:2635-2638.
77. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N (2003) Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 13:554-573.
78. Grossi C, Francese S, Casini A, Rosi MC, Luccarini I, Fiorentini A, Gabbiani C, Messori L, Moneti G, Casamenti F (2009) Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgeneic mouse model of Alzheimer's disease. J Alzheimers Dis 17:423-440.
79. Guo C, Wang T, Zheng W, Shan ZY, Teng WP, Wang ZY (2013a) Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 34:562-575.
80. Guo C, Wang P, Zhong ML, Wang T, Huang XS, Li JY, Wang ZY (2013b) Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem Int 62:165-172.
81. Guy J, McGorray S, Qi X, Fitzsimmons J, Mancuso A, Rao N (1994) Conjugated deferoxamine reduces blood-brain barrier disruption in experimental optic neuritis. Ophthalmic Res. 26:310-323.
82. Haacke EM, Makki M, Ge Y, Maheshwari M, Sehgal V, Hu J, Selvan M, Wu Z, Latif Z, Xuan Y, Khan O, Garbern J, Grossman RI (2009) Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 29:537-544.
83. Habgood MD, Liu ZD, Dehkordi LS, Khodr HH, Abbott J, Hider RC (1999) Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability. Biochem Pharmacol. 57:1305-1310.
84. Hagemeier J, Weinstock-Guttman B, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Magnano C, Hojnacki D, Dwyer MG, Zivadinov R (2012) Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy. AJNR Am J Neuroradiol 33:1596-1601.
85. Hagemeier J, Yeh EA, Brown MH, Bergsland N, Dwyer MG, Carl E, Weinstock-Guttman B, Zivadinov R (2013) Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. Mult Scler 19:567-576.
86. Hametner S, Wimmer I, Haider L, Pfeifenbring S, Brück W, Lassmann H (2013) Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol, doi: 10.1002/ana.23974.
87. Hammond KE, Metcalf M, Carvajal L, Okuda DT, Srinivasan R, Vigneron D, Nelson SJ, Pelletier D (2008) Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 64:707-713.
88. Hanson LR, Roeyetenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ, Marti DL, Hoekman JD, Matthews RB, Frey WH 2nd, Panter SS (2009) Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther 330:679-686.
89. Hanson LR, Fine JM, Renner DB, Svitak AL, Burns RB, Nguyen TM, Tuttle NJ, Marti DL, Panter SS, Frey WH 2nd (2012) Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice. Drug Deliv Transl Res 2:160-168.
90. Hare D, Ayton S, Bush A, Lei P (2013) A delicate balance: iron metabolism and diseases of the brain. Front Aging Neurosci 5:34.
91. He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S (2012) Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev 12:CD009882.
92. Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT (2004) Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann NY Acad Sci 1012:153-163.
93. Hulet SW, Powers S, Connor JR (1999) Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains. J Neurol Sci 165:48-55.
94. Hunter S, Arendt T, Brayne C (2013) The senescence hypothesis of disease progression in Alzheimer disease: an integrated matrix of disease pathways for FAD and SAD. Mol Neurobiol, in the press.
95. Hvidberg V, Maniecki MB, Jacobsen C, Højrup P, Møller HJ, Moestrup SK (2005) Identification of the receptor scavenging hemopexin-heme complexes. Blood 106:2572-2579.
96. Im DS, Jeon JW, Lee JS, Won SJ, Cho SI, Lee YB, Gwag BJ (2012) Role of the NMDA receptor and iron on free radical production and brain damage following transient middle cerebral artery occlusion. Brain Res 1455:114-123.
97. Jadidi-Niaragh F, Mirshafiey A (2011) Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol 74:1-13.
98. Jamuar SS, Lai AH (2012) Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia. Ther Adv Hematol 3:299-307.
99. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL (1997) Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem 272:19253-19260.
100. Kadiiska MB, Burkitt MJ, Xiang QH, Mason RP (1995) Iron supplementation generates hydroxyl radical in vivo. An ESR spin-trapping investigation. J Clin Invest 96:1653-1657.
101. Kakhlon O, Manning H, Breuer W, Melamed-Book N, Lu C, Cortopassi G (2008) Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood 112:5219-5227.
102. Kakhlon O, Breuer W, Munnich A, Cabantchik ZI (2010) Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation. Can J Physiol Pharmacol 88:187-196.
103. Kang JH, Chen YH, Lin HC (2010) Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol 17:1215-1219.
104. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37:899-909.
105. Kaur D, Rajagopalan S, Chinta S, Kumar J, Di Monte D, Cherny RA, Andersen JK (2007) Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration. Brain Res 1140:188-194.
106. Kaur D, Rajagopalan S, Andersen JK (2009) Chronic expression of H-ferritin in dopaminergic midbrain neurons results in an age-related expansion of the labile iron pool and subsequent neurodegeneration: implications for Parkinson's disease. Brain Res 1297:17-22.
107. Khalil M, Enzinger C, Langkammer C, Tscherner M, Wallner-Blazek M, Jehna M, Ropele S, Fuchs S, Fazekas F (2009) Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler 15:1048-1054.
108. Koeppen AH (2011) Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 303:1-12.
109. Kuvibidila SR, Kitchens D, Baliga BS (1999) In vivo and in vitro iron deficiency reduces protein kinase C activity and translocation in murine splenic and purified T cells. J Cell Biochem 74:468-478.
110. Kuvibidila SR, Velez M, Yu L, Warrier RP, Surendra Baliga B (2002) Differences in iron requirements by concanavalin A-treated and anti-CD3-treated murine splenic lymphocytes. Br J Nutr 88:67-72.
111. Kwiatkowski J (2011) Real-world use of iron chelators. Hematology Am Soc Hematol Educ Program 2011:451-458.
112. Kwiatkowski A, Ryckewaert G, Jissendi Tchofo P, Moreau C, Vuillaume I, Chinnery PF, Destée A, Defebvre L, Devos D (2012) Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. Parkinsonism Relat Disord 18:110-112.
113. Lassmann H (2011) Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease. J Neural Transm 118:747-752.
114. Lederman HM, Cohen A, Lee JW, Freedman MH, Gelfand EW (1984) Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 64:748-753.
115. Lehmann-Horn K, Kronsbein HC, Weber MS (2013) Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther Adv Neurol Disord. 6:161-173.
116. Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, Wong BX, Adlard PA, Cherny RA, Lam LQ, Roberts BR, Volitakis I, Egan GF, McLean CA, Cappai R, Duce JA, Bush AI (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 18:291-295.
117. Leskovjan AC, Kretlow A, Lanzirotti A, Barrea R, Vogt S, Miller LM (2011) Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer's disease. Neuroimage 55:32-38.
118. Leung S, Holbrook A, King B, Lu HT, Evans V, Miyamoto N, Mallari C, Harvey S, Davey D, Ho E, Li WW, Parkinson J, Horuk R, Jaroch S, Berger M, Skuballa W, West C, Pulk R, Phillips G, Bryant J, Subramanyam B, Schaefer C, Salamon H, Lyons E, Schilling D, Seidel H, Kraetzschmar J, Snider M, Perez D (2005) Differential inhibition of inducible T cell cytokine secretion by potent iron chelators. J Biomol Screen 10:157-167.
119. LeVine SM (1997) Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res 760:298-303.
120. LeVine SM, Maiti S, Emerson MR, Pedchenko TV (2002) Apoferritin attenuates experimental allergic encephalomyelitis in SJL mice. Dev Neurosci 24:177-183.
121. LeVine SM, Chakrabarty A (2004) The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann NY Acad Sci 1012:252-266.
122. LeVine SM, Bilgen M, Lynch SG (2013) Iron accumulation in multiple sclerosis: an early pathogenic event. Expert Rev Neurother 13:247-250.
123. Levy M, Turtzo C, Llinas RH (2007) Superficial siderosis: a case report and review of the literature. Nat Clin Pract Neurol 3:54-58.
124. Levy M, Llinas RH (2012a) Pilot safety trial of deferiprone in 10 subjects with superficial siderosis. Stroke 43:120-124.
125. Levy M, Llinas RH (2012b) Update on a patient with superficial siderosis on deferiprone. AJNR Am J Neuroradiol 33:E99-E100.
126. Li H, Swiercz R, Englander E (2009) Elevated metals compromise repair of oxidative DNA damage via the base excision repair pathway: implications of pathologic iron overload in the brain on integrity of neuronal DNA. J Neurochem 110:1774-1783.
127. Liang LP, Jarrett SG, Patel M (2008) Chelation of mitochondrial iron prevents seizure-induced mitochondrial dysfunction and neuronal injury. J Neurosci 28:11550-11556.
128. Liddell JR, Obando D, Liu J, Ganio G, Volitakis I, Mok SS, Crouch PJ, White AR, Codd R (2013) Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease. Free Radic Biol Med 60:147-156.
129. Liu Y, Zhu B, Luo L, Li P, Paty DW, Cynader MS (2001) Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. NeuroReport 12:1841-1845.
130. Loréal O, Turlin B, Pigeon C, Moisan A, Ropert M, Morice P, Gandon Y, Jouanolle AM, Vérin M, Hider RC, Yoshida K, Brissot P (2002) Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol 36:851-856.
131. Lu F, Selak M, O'Connor J, Croul S, Lorenzana C, Butunoi C, Kalman B (2000) Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci 177:95-103.
132. Lu N, Li X, Li J, Xu W, Li H, Gao Z (2011) Nitrative and oxidative modifications of enolase are associated with iron in iron-overload rats and in vitro. J Biol Inorg Chem 16:481-490.
133. Lynch SG, Peters K, LeVine SM (1996) Desferrioxamine in chronic progressive multiple sclerosis: a pilot study. Mult Scler 2:157-160.
134. Lynch SG, Fonseca T, LeVine SM (2000) A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cell Mol Biol (Noisy-le-grand) 46:865-869.
135. Ma Y, Roy S, Kong X, Chen Y, Liu D, Hider RC (2012) Design and synthesis of fluorinated iron chelators for metabolic study and brain uptake. J Med Chem 55:2185-2195.
136. Mahad D, Lassmann H, Turnbull D (2008) Review: Mitochondria and disease progression in multiple sclerosis. Neuropathol Appl Neurobiol 34:577-589.
137. Mairuae N, Connor J, Cheepsunthorn P (2011) Increased cellular iron levels affect matrix metalloproteinase expression and phagocytosis in activated microglia. Neurosci Lett 500:36-40.
138. Mao P, Reddy P (2010) Is multiple sclerosis a mitochondrial disease? Biochim Biophys Acta 1802:66-79.
139. Mariani R, Arosio C, Pelucchi S, Grisoli M, Piga A, Trombini P, Piperno A (2004) Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. Gut 53:756-758.
140. Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S (2003) Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60:1676-1679.
141. Mastroberardino P, Hoffman E, Horowitz M, Betarbet R, Taylor G (2009) A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol Dis 34:417-431.
142. Matute C (2011) Glutamate and ATP signalling in white matter pathology. J Anat 219:53-64.
143. McGahan M, Harned J, Mukunnemkeril M, Goralska M, Fleisher L, Ferrell JB (2005) Iron alters glutamate secretion by regulating cytosolic aconitase activity. Am J Physiol Cell Physiol 288:1117-1124.
144. Mehindate K, Sahlas DJ, Frankel D, Mawal Y, Liberman A, Corcos J, Dion S, Schipper HM (2001) Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J Neurochem 77:1386-1395.
145. Mehta V, Pei W, Yang G, Li S, Swamy E, Boster A, Schmalbrock P, Pitt D (2013) Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS ONE 8:e57573.
146. Merkofer M, Kissner R, Hider RC, Brunk UT, Koppenol WH (2006) Fenton chemistry and iron chelation under physiologically relevant conditions: electrochemistry and kinetics. Chem Res Toxicol 19:1263-1269.
147. Mitchell KM, Dotson AL, Cool KM, Chakrabarty A, Benedict SH, LeVine SM (2007) Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis. Mult Scler 13:1118-1126.
148. Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin JD (1997) Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 41:404-407.
149. Mole DR (2010) Iron homeostasis and its interaction with prolyl hydroxylases. Antioxid Redox Signal 12:445-458.
150. Molina-Holgado F, Gaeta A, Francis PT, Williams RJ, Hider RC (2008) Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. J Neurochem 105:2466-2476.
151. Nakamura T, Keep RF, Hua Y, Schallert T, Hoff JT, Xi G (2004) Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. J Neurosurg 100:672-678.
152. Neema M, Arora A, Healy BC, Guss ZD, Brass SD, Duan Y, Buckle GJ, Glanz BI, Stazzone L, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R (2009) Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging 19:3-8.
153. Norstrand IF, Craelius W (1989) A trial of deferoxamine (Desferal*) in the treatment of multiple sclerosis. A pilot study. Clinical Trials J 26:365-369.
154. Onyango I, Lu J, Rodova M, Lezi E, Crafter A, Swerdlow RH (2010) Regulation of neuron mitochongrial biogenesis and relevance to brain health. Biochim Biophys Acta 1802:228-234.
155. Papazisis G, Pourzitaki C, Sardeli C, Lallas A, Amaniti E, Kouvelas D (2008) Deferoxamine decreases the excitatory amino acid levels and improves the histological outcome in the hippocampus of the neonatal rats after hypoxia-ischemia. Pharmacol Res 57:73-78.
156. Parkinson MH, Schulz JB, Giunti P (2013) Co-enzyme Q10 and idebenone use in Friedreich's ataxia. Neurochemistry 126 (Suppl 1):125-141.
157. Pedchenko T, LeVine SM (1998) Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice. J Neuroimmunol 84:188-197.
158. Pelizzoni I, Macco R, Morini MF, Zacchetti D, Grohovaz F, Codazzi F (2011) Iron handling in hippocampal neurons: activity-dependent iron entry and mitochondria-mediated neurotoxicity. Aging Cell 10:172-183.
159. Pitt D, Werner P, Raine CS (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6:67-70.
160. Pitt D, Boster A, Pei W, Wohleb E, Jasne A, Zachariah CR, Rammohan K, Knopp MV, Schmalbrock P (2010) Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol 67:812-818.
161. Porter J (2009) Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev 23 (Suppl 1):S3-S7.
162. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231.
163. Prass K, Ruscher K, Karsch M, Isaev N, Megow D, Priller J, Scharff A, Dirnagl U, Meisel A (2002) Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J Cereb Blood Flow Metab 22:520-525.
164. Pratini NR, Sweeters N, Vichinsky E, Neufeld JA (2013) Treatment of classic pantothenate kinase-associated neurodegeneration with Deferiprone and intrathecal Baclofen. Am J Phys Med Rehabil 92:728-733.
165. Rajesh M, Sulochana K, Ramakrishnan S, Biswas J, Manoharan P (2004) Iron chelation abrogates excessive formation of hydroxyl radicals and lipid peroxidation products in monocytes of patients with Eales' disease: direct evidence using electron spin resonance spectroscopy. Curr Eye Res 28:399-407.
166. Rajeswari MR (2012) DNA triplex structures in neurodegenerative disorder, Friedreich's ataxia. J Biosci 37:519-532.
167. Rathnasamy G, Ling EA, Kaur C (2011) Iron and iron regulatory proteins in amoeboid microglial cells are linked to oligodendrocyte death in hypoxic neonatal rat periventricular white matter through production of proinflammatory cytokines and reactive oxygen/nitrogen species. J Neurosci 31:17982-17995.
168. Rathnasamy G, Ling EA, Kaur C (2013) Hypoxia inducible factor-1α mediates iron uptake which induces inflammatory response in amoeboid microglial cells in developing periventricular white matter through MAP kinase pathway. Neuropharmacology 77:428-440.
169. Rathore KI, Redensek A, David S (2012) Iron homeostasis in astrocytes and microglia is differentially regulated by TNF-α and TGF-β1. Glia 60:738-750.
170. Reznichenko L, Amit T, Zheng H, Avramovich-Tirosh Y, Youdim MB, Weinreb O, Mandel S (2006) Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem 97:527-536.
171. Richardson DR, Mouralian C, Ponka P, Becker E (2001) Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim Biophys Acta 1536:133-140.
172. Ristori G, Brescianini S, Pino A, Visconti A, Vittori D, Coarelli G, Cotichini R, Bocca B, Forte G, Pozzilli C, Pestalozza I, Stazi MA, Alimonti A, Salvetti M (2011) Serum elements and oxidative status in clinically isolated syndromes: imbalance and predictivity. Neurology 76:549-555.
173. Robinson SR, Dang TN, Dringen R, Bishop GM (2009) Hemin toxicity: a preventable source of brain damage following hemorrhagic stroke. Redox Rep 14:228-235.
174. Rodrigo L, Hernández-Lahoz C, Fuentes D, Alvarez N, López-Vázquez A, González S (2011) Prevalence of celiac disease in multiple sclerosis. BMC Neurol 11:31.
175. Rolla S, Ingoglia G, Bardina V, Silengo L, Altruda F, Novelli F, Tolosano E (2013) Acute-phase protein hemopexin is a negative regulator of th17 response and experimental autoimmune encephalomyelitis development. J Immunol 191:5451-5459.
176. Rossi S, Motta C, Studer V, Barbieri F, Buttari F, Bergami A, Sancesario G, Bernardini S, De Angelis G, Martino G, Furlan R, Centonze D (2013) Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration, Mult Scler, in the press.
177. Roy S, Preston J, Hider R, Ma Y (2010) Glucosylated deferiprone and its brain uptake: implications for developing glucosylated hydroxypyridinone analogues intended to cross the blood-brain barrier. J Med Chem 53:5886-5889.
178. Sayre LM, Peerry G, Harris PL, Liu Y, Schubert KA, Smith MA (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J. Neurochem 74:270-279.
179. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM (2013) Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 121:1276-1284.
180. Schäfer S, Pajonk FG, Multhaup G, Bayer TA (2007) Copper and clioquinol treatment in young APP transgenic and wild-type mice: effects on life expectancy, body weight, and metal-ion levels. J Mol Med (Berl) 85:405-413.
181. Schneider SA, Zorzi G, Nardocci N (2013) Pathophysiology and treatment of neurodegeneration with brain iron accumulation in the pediatric population. Curr Treat Options Neurol. 15:652-667.
182. Schofield CJ, Ratcliffe PJ (2005) Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun 338:617-626.
183. Schulz K, Vulpe CD, Harris LZ, David S (2011) Iron efflux from oligodendrocytes is differentially regulated in gray and white matter. J Neurosci 31:13301-13311.
184. Sedgwick J, Brostoff S, Mason D (1987) Experimental allergic encephalomyelitis in the absence of a classical delayed-type hypersensitivity reaction. Severe paralytic disease correlates with the presence of interleukin 2 receptor-positive cells infiltrating the central nervous system. J Exp Med 165:1058-1075.
185. Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148:399-408.
186. Shijie J, Takeuchi H, Yawata I, Harada Y, Sonobe Y, Doi Y, Liang J, Hua L, Yasuoka S, Zhou Y, Noda M, Kawanokuchi J, Mizuno T, Suzumura A (2009) Blockade of glutamate release from microglia attenuates experimental autoimmune encephalomyelitis in mice. Tohoku J Exo Med 217:87-92.
187. Singh N, Sharma G, Mishra V (2012) Hypoxia inducible factor-1: its potential in cerebral ischemia. Cell Mol Neurobiol 32:491-507.
188. Smith MA, Harris PL, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94:9866-9868.
189. Smith T, Groom A, Zhu B, Turski L (2000) Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6:62-66.
190. Sohn YS, Breuer W, Munnich A, Cabantchik ZI (2008) Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 111:1690-1699.
191. Srinivasan R, Ratiney H, Hammond-Rosenbluth K, Pelletier D, Nelson S (2010) MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. Magn Reson Imaging 28:163-170.
192. Stahnke T, Stadelmann C, Netzler A, Brück W, Richter-Landsberg C (2007) Differential upregulation of heme oxygenase-1 (HSP32) in glial cells after oxidative stress and in demyelinating disorders. J Mol Neurosci 32:25-37.
193. Su K, Bourdette D, Forte M (2013) Mitochondrial dysfunction and neurodegeneration in multiple sclerosis. Front Physiol 4:169.
194. Sun YY, Wang CY, Hsu MF, Juan SH, Chang CY, Chou CM, Yang LY, Hung KS, Xu J, Lee YH, Hsu CY (2010) Glucocorticoid protection of oligodendrocytes against excitotoxin involving hypoxia-inducible factor-1alpha in a cell-type-specific manner. J Neurosci 30:9621-9630.
195. Sweeney ME, Slusser JG, Lynch SG, Benedict SH, Garcia SL, Rues L, LeVine SM (2011) Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects. Int Immunopharmacol 11:1796-1801.
196. Szuber N, Buss JL, Soe-Lin S, Felfly H, Trudel M, Ponka P (2008) Alternative treatment paradigm for thalassemia using iron chelators. Exp Hematol 36:773-785.
197. Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR (2009) Oligodendrocytes and myelination: the role of iron. Glia 57:467-478.
198. Tjoa C, Benedict R, Weinstock-Guttman B, Fabiano A, Bakshi R (2005) MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J Neurol Sci 234:17-24.
199. van Rensburg SJ, Kotze MJ, van Toorn R (2012) The conundrum of iron in multiple sclerosis-time for an individualised approach. Metab Brain Dis 27:239-253.
200. van Toorn R, Schoeman JF, Solomons R, Rensburg MA, van Rensburg SJ (2010) Iron status in children with recurrent episodes of tumefactive cerebral demyelination. J Child Neurol 25:1401-1407.
201. Vaubel RA, Isaya G (2013) Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia. Mol Cell Neurosci 55:50-61.
202. Velasco-Sánchez D, Aracil A, Montero R, Mas A, Jiménez L, O'Callaghan M, Tondo M, Capdevila A, Blanch J, Artuch R, Pineda M (2011) Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 10:1-8.
203. Vladimirova O, O'Connor J, Caill A, Alder H, Butunoi C, Kalman B (1998) Oxidative damage to DNA in plaques of MS brains. Mult Scler 4:413-418.
204. Wakefield AJ, More LI, Difford J, McLaughlin JE (1994) Immunohistochemical study of vascular injury in acute multiple sclerosis. J Clin Pathol 47:129-133.
205. Warnke C, Meyer Zu Hörste G, Hartung HP, Stüve O, Kieseier BC (2009) Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 5:333-340.
206. Weilbach FX, Chan A, Toyka KV, Gold R (2004) The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol 135:49-55.
207. Weiner HL, Ellison GW (1983) A working protocol to be used as a guideline for trials in multiple sclerosis. Arch Neurol 40:704-710.
208. Weinreb O, Mandel S, Youdim MB, Amit T (2013) Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic Biol Med 62:52-64.
209. Werner P, Pitt D, Raine C (2001) Multiple sclerosis: altered glutamate homoeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50:169-180.
210. Willenborg DO, Bowern NA, Danta G, Doherty PC (1988) Inhibition of allergic encephalomyelitis by the iron chelating agent desferrioxamine: differential effect depending on type of sensitizing encephalitogen. J Neuroimmunol 17:127-135.
211. Williams R, Rohr AM, Wang WT, Choi IY, Lee P, Berman NE, Lynch SG, LeVine SM (2011) Iron deposition is independent of cellular inflammation in a cerebral model of multiple sclerosis. BMC Neurosci 12:59.
212. Williams R, Buchheit CL, Berman N, LeVine SM (2012) Pathogenic implications of iron accumulation in multiple sclerosis. J Neurochem 120:7-25.
213. Wosik K, Ruffini F, Almazan G, Olivier A, Nalbantoglu J, Antel JP (2004) Resistance of human adult oligodendrocytes to AMPA/kainate receptor-mediated glutamate injury. Brain 127:2636-2648.
214. Wu G, Walker J, Rao N (1993) Effect of deferoxamine on retinal lipid peroxidation in experimental uveitis. Invest Ophthalmol Vis Sci. 34:3084-3089.
215. Wu G, Sun S, Sheng F, Wang L, Wang F (2013) Perihematomal glutamate level is associated with the blood-brain barrier disruption in a rabbit model of intracerebral hemorrhage. SpringerPlus 2:358.
216. Yamawaki T (2012) Clinical features of superficial siderosis. Rinsho Shinkeigaku 52:937-950.
217. Yao SY, Soutto M, Sriram S (2008) Preconditioning with cobalt chloride or desferrioxamine protects oligodendrocyte cell line (MO3.13) from tumor necrosis factor-alpha-mediated cell death. J Neurosci Res 86: 2403-2413.
218. Yassin MS, Ekbolm J, Xilinas M, Gottfries CG, Oreland L (2000) Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci 173:40-44.
219. Yi C, Yang CG, He C (2009) A non-heme iron-mediated chemical demethylation in DNA and RNA. Acc Chem Res 42:519-529.
220. Youdim MB, Stephenson G, Ben Shachar D (2004) Ironing iron out in Parkinson's disease and other neurodegenerative disease with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann NY Acad Sci. 1012:306-325.
221. Yu J, Guo Y, Sun M, Li B, Zhang Y, Li C (2009) Iron is a potential key mediator of glutamate excitotoxicity in spinal cord motor neurons. Brain Res 1257:102-107.
222. Zhang X, Haaf M, Todorich B, Grosstephan E, Schieremberg H, Surguladze N, Connor JR (2005) Cytokine toxicity to oligodendrocyte precursors is mediated by iron. Glia 52:199-208.
223. Zhang S, Wang J, Song N, Xie J, Jiang H (2009) Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MMP(+))-induced apoptosis in MES23.5 cells. Neurobiol Aging 30:1466-1476.
224. Zhang X, Surguladze N, Slagle-Webb B, Cozzi A, Connor J (2006) Cellular iron status influences the functional relationship between microglia and oligodendrocytes. Glia 54:795-804.
225. Zhang Y, Zabad R, Wei X, Metz L, Hill M, Mitchell J (2007) Deep grey matter "black T2" on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosis. Mult Scler 13:880-883.
226. Zhang Z, Zhang ZY, Schittenhelm J, Wu Y, Meyermann R, Schluesener HJ (2011) Parenchymal accumulation of CD163+ macrophages/microglia in multiple sclerosis brains. J Neuroimmunol 237:73-79.
227. Zhao Y, Rempe DA (2011) Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. J Cereb Blood Flow Metab 31:1412-1423.
228. Zhu Y, Zhang L, Gidday JM (2008) Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance. J Ocul Pharmacol Ther 24:527-535.
229. Zorzi G, Zibordi F, Chiapparini L, Bertini E, Russo L, Piga A, Longo F, Garavaglia B, Aquino D, Savoiardo M, Solari A, Nardocci N (2011) Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord 26:1756-1759.